Voetterl, Helena T. S. http://orcid.org/0000-0003-0342-9737
Sack, Alexander T. http://orcid.org/0000-0002-1471-0885
Olbrich, Sebastian http://orcid.org/0000-0001-5557-4878
Stuiver, Sven http://orcid.org/0000-0002-5260-0820
Rouwhorst, Renee
Prentice, Amourie http://orcid.org/0000-0002-7050-7216
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
van der Vinne, Nikita http://orcid.org/0009-0000-9459-2729
van Waarde, Jeroen A. http://orcid.org/0000-0001-6792-5727
Brunovsky, Martin http://orcid.org/0000-0002-2483-0848
van Oostrom, Iris
Reitsma, Ben
Fekkes, Johan
van Dijk, Hanneke
Arns, Martijn http://orcid.org/0000-0002-0610-7613
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Czech Science Foundation
Article History
Received: 5 April 2023
Accepted: 10 October 2023
First Online: 16 November 2023
Competing interests
: The authors declare the following competing interests: A.T.S. is Chief Scientific Advisor of PlatoScience and Alphasys, Founder of Neurowear Medical B.V., received equipment support from MagVenture, Deymed, and MagStim Company, and is Scientific Director of the International Clinical TMS Certification Course (ExternalRef removed). S.O. is cofounder of DeepPsy, a company for EEG-biomarker report systems. Over the past 3 years, D.A.P. has received consulting fees from Albright Stonebridge Group, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sage Therapeutics, Sunovion and Takeda; he has received honoraria from the Psychonomic Society and the American Psychological Association (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, the Dana Foundation, Millennium Pharmaceuticals, National Institute of Mental Health (NIMH), and Wellcome Leap; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. M.B. declares to have shares in ‘Psyon s.r.o’ and is involved in Compass Pathways trials with psilocybin and MAPS clinical trial with MDMA outside the submitted work. He has founded ‘PSYRES - Psychedelic Research Foundation’ and has shares in ‘Společnost pro podporu neurovědního výzkumu s.r.o’. M.A. holds equity/stock in neurocare and Sama Therapeutics, serves as consultant to Synaeda and Sama Therapeutics, and is named inventor on neurocare owned patent, but receives no royalties; Research Institute Brainclinics received research and consultancy support from neurocare and equipment support from neuroconn and Deymed. Brainmarker-I as described in this manuscript is offered by the non-profit mental health clinic Synaeda PMC (Leeuwarden, the Netherlands), where it is also used in practice. Authors H.T.S.V., S.S., R.R., A.P., N.v.V., J.A.v.W., M.B., I.v.O., B.R., J.F. and H.v.D. report no conflicts of interest.